☆ 4.7 Meeting Abstract

Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 34, Issue 4, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2016.34.4_suppl.439

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial

Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem

Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.

ECLINICALMEDICINE (2023)

Add to Collection

Letter Oncology

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study

Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng

Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Article Oncology

hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma

Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane

Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study

Nicolas Williet, Angelica Petrillo, Gael Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, Jean Marc Phelip

Summary: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) were found to have no significant difference as first-line treatments in patients with locally advanced pancreatic cancer (LAPC) in terms of survival, tumor response, or tumor resection rate, according to a multicenter European study. Further trials are needed to confirm these findings.

CANCERS (2021)

Add to Collection

Article Oncology

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

Jaime Feliu, Monica Jorge Fernandez, Teresa Macarulla, Bartomeu Massuti, Ana Albero, Jose Federico Gonzalez Gonzalez, Guillermo Quintero-Aldana, Juan Ignacio Delgado-Mingorance, Ana Fernandez Montes, Carmen Garcia Piernavieja, Manuel Valladares-Ayerbes, Ana Maria Lopez Munoz, Rebeca Mondejar Solis, Pilar Vicente, Esther Casado Gonzalez, Irene Gonzalez Cebrian, Guillermo Lopez-Vivanco

Summary: This study aimed to evaluate the health-related quality of life, global health status, and survival of elderly patients with unresectable pancreatic cancer treated with nab-paclitaxel and gemcitabine. The results showed improved survival and clinical response in the elderly population, but did not confirm a benefit in terms of quality of life.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella

Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

Volker Kunzmann, Jens T. Siveke, Hana Alguel, Eray Goekkurt, Gabriele Siegler, Uwe Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Swantje Held, Ralph Keller, Ingo Klein, Christoph-Thomas Germer, Hubert Stein, Helmut Friess, Marcus Bahra, Ralf Jakobs, Ingo Hartlapp, Volker Heinemann

Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Oncology

Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer

Shuichi Mitsunaga, Masafumi Ikeda, Hiroshi Imaoka, Mitsuhito Sasaki, Kazuo Watanabe, Akihiro Sato, Kazunori Aoki, Atsushi Ochiai, Mayu Makikawa, Masanobu Nishidate, Kyoko Yamaguchi, Kimio Terao, Noriaki Sawada, Takashi Fujitomo, Etsuko Fujii, Atsuhiko Kato, Hiroyuki Tsunoda

Summary: Inhibition of the IL-6/STAT3 pathway can overcome chemoresistance in metastatic pancreatic cancer. This study found that using the IL-6 receptor monoclonal antibody TCZ can overcome chemoresistance and a recommended dose of 8 mg/kg was determined. The results showed that TCZ can inhibit the proliferation of cancer-associated fibroblasts and improve drug infiltration in the tumor.

CANCER SCIENCE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer

Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti

Summary: The study found that FFX and GN have equivalent efficacy in first-line treatment of metastatic pancreatic cancer, but differ in safety profiles. Anemia was more frequent in the GN group, while higher occurrences of vomiting and diarrhea were reported in the FFX group.

BIOMOLECULES (2021)

Add to Collection

Article Oncology

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou

Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran

Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Gemcitabine plus Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot

Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer

Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Naohiro Okano, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Hiroshi Imaoka, Tatsuya Yamashita, Haruo Miwa, Hiroaki Nagano, Shiho Arima, Hideyuki Hayashi, Atsushi Naganuma, Hironori Yamaguchi, Terumasa Hisano, Kumiko Umemoto, Shuji Ishii, Koji Nakashima, Rei Suzuki, Yohei Kitano, Toshihiro Misumi, Junji Furuse, Hiroshi Ishii

Summary: This study investigated the efficacy and safety of Gemcitabine plus nab-paclitaxel (GnP) compared to other treatments in older adults with unresectable pancreatic cancer (uPC). The results showed that GnP was more effective than Gem in patients aged 76 years and older, despite a higher incidence of severe adverse events.

ONCOLOGIST (2022)

Add to Collection

Article Oncology

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

Patrick M. Grierson, Benjamin Tan, Katrina S. Pedersen, Haeseong Park, Rama Suresh, Manik A. Amin, Nikolaos A. Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J. Der, Andrea Wang-Gillam, Kian-Huat Lim

Summary: This study evaluated the efficacy and safety of ulixertinib combined with gemcitabine and nab-paclitaxel (GnP) for untreated metastatic pancreatic adenocarcinoma. The results showed that ulixertinib plus GnP had similar toxicity and efficacy as GnP, but was complicated by a high rate of all-grade treatment-related adverse events (TRAEs).

ONCOLOGIST (2023)

Add to Collection

Article Oncology

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer

Marzia Del Re, Caterina Vivaldi, Eleonora Rofi, Francesca Salani, Stefania Crucitta, Silvia Catanese, Lorenzo Fontanelli, Valentina Massa, Federico Cucchiara, Lorenzo Fornaro, Annalisa Capuano, Stefano Fogli, Enrico Vasile, Romano Danesi

Summary: This study investigated the effects of two standard-of-care chemotherapeutic regimens on PD-L1 mRNA expression in pancreatic cancer patients. The findings suggest that GEMnPAC regimen may increase PD-L1 mRNA expression, providing a rationale for potential combination with immunotherapy in PDAC patients.

CANCERS (2021)

Add to Collection

Article Oncology

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara E. Seery, William P. Harris, Darren S. Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, Paul E. Oberstein, Andrea Wang-Gillam, Wilson Wu, Dimitrios Chondros, Ping Jiang, Sihem Khelifa, Jie Pu, Carrie Aldrich, Andrew E. Hendifar

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Meeting Abstract Oncology

Three-fold overestimation of tumor mutation burden using 248 gene panel versus whole exome.

Andrew Nguyen, Chad Garner, Sandeep K. Reddy, John Z. Sanborn, Stephen Charles Benz, Tara Elisabeth Seery, Shahrooz Rabizadeh

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Alexander Drilon, Siqing Fu, Manish R. Patel, Marwan Fakih, Ding Wang, Anthony J. Olszanski, Daniel Morgensztern, Stephen V. Liu, Byoung Chul Cho, Lyudmila Bazhenova, Cristina P. Rodriguez, Robert C. Doebele, Antoinette Wozniak, Karen L. Reckamp, Tara Seery, Petros Nikolinakos, Zheyi Hu, Jennifer W. Oliver, Denise Trone, Katherine McArthur, Rupal Patel, Pratik S. Multani, Myung-Ju Ahn

CANCER DISCOVERY (2019)

Add to Collection

Meeting Abstract Oncology

NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Tara Elisabeth Seery, John H. Lee, Leonard S. Sender, Frank R. Jones, Arvind Manohar Shinde, Anand Annamalai, Mira Kistler, Omid Jafari, Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Clinical trial screening of CDKN2A genomic alterations in patients with pancreatic cancer and hepatobiliary cancers requires greater precision than somatic sequencing alone.

Charles Joseph Vaske, Chad Garner, Tara Elisabeth Seery, Christopher Szeto, Sandeep K. Reddy

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip, Sunil R. Hingorani, Jill Lacy, Jeremy S. Kortmansky, Jaykumar Thumar, E. Gabriela Chiorean, Anthony F. Shields, Deepti Behl, Paul T. Mehan, Rakesh Gaur, Tara Seery, Katherine Guthrie, Howard S. Hochster

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Tara Elisabeth Seery, Mira Kistler, Leonard S. Sender, John H. Lee, Arvind Manohar Shinde, Anand Annamalai, Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.

Chad Garner, Tara Elisabeth Seery, Chaitali Singh Nangia, John H. Lee, Liyang Huang, Leonard S. Sender, Shahrooz Rabizadeh, Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

P. Hammel, H. L. Kindler, M. Reni, E. Van Cutsem, T. Macarulla, M. J. Hall, J. O. Park, D. Hochhauser, D. Arnold, D-Y Oh, A. Reinacher-Schick, G. Tortora, H. Alguel, E. M. O'Reilly, D. McGuinness, K. Y. Cui, S. Joo, H. K. Yoo, N. Patel, T. Golan, Lorraine Chantrill, David Goldstein, Warren Joubert, Nick Pavlakis, Annette Tognela, Eric Van Cutsem, Frank Van Fraeyenhove, Jean-Luc Van Laethem, Marc Peeters, Neesha Dhani, Petr Kavan, Frederic Lemay, Antoine Adenis, Pascal Artru, Nabil Hamed, Christine Belletier, Meher Ben Abdelghani, Jean-Frederic Blanc, Christophe Borg, Romain Coriat, Gael Deplanque, Roger Faroux, Philippe Follana, Rosine Guimbaud, Farid el Hajbi, Pascal Hammel, Vincent Hautefeuille, David Malka, Jean-Philippe Metges, David Tougeron, Thomas Walter, Hana Alguel, Thomas Ettrich, Ulrich Thorsten Hacker, Elke Hennes, Lutz Jacobasch, Stephan Kanzler, Ursula Pession, Anke Reinacher-Schick, Christian Scholz, Marianne Sinn, Alexander Stein, Christian Strassburg, Arndt Vogel, Menachem Ben-Shahar, Ronen Brenner, Ron Epelbaum, Ravit Geva, Alexander Gluzman, Talia Golan, Efraim Idelevich, Maya Kolin, Valeriya Semenisty, Ayelet Shai, Salomon Stemmer, Nirit Yarom, Luigi Celio, Pierfranco Conte, Carlo Garufi, Luca Gianni, Francesco Leonardi, Evaristo Maiello, Mariacristina Di Marco, Michele Milella, Carmine Pinto, Daniele Santini, Mario Scartozzi, Giampaolo Tortora, Vanja Vaccaro, Enrico Vasile, Ji-Won Kim, Jin-Won Kim, Youn Oh, Joon Oh Park, Hanneke Wilmink, Rafael Alvarez Gallego, Gema Duran Ogalla, Adelaida Garcia Velasco, Elena Garralda Cabanas, Carlos Gomez Martin, Carmen Guillen Ponce, Berta Laquente Saez, Rafael Lopez, Teresa Macarulla, Andres Munoz Martin, Roberto Pazo, Carles Pericay Pijaume, Javier Rodriguez, Ricardo Yaya-Tur, Arvind Arora, David Alan Anthoney, T. R. Jeffrey Evans, Mark Harrison, Daniel Hochhauser, Daniel Palmer, Debashis Sarker, Naureen Starling, Juan Valle, Lucy Wall, Richy Agajanian, James Bearden, Tanios Bekaii-Saab, Corey Carter, Deirdre Cohen, Alfred DiStefano, Tomislav Dragovich, Samuel Ejadi, James Ford, Stephen Grabelsky, Michael Hall, Howard Hochster, Peter Hosein, Milind Javle, Hedy Kindler, Jill Lacy, Daniel Laheru, Stephen Leong, Maeve Lowery, Robert Marsh, Anne Noonan, Paul Oberstein, Allyson Ocean, Eileen O'Reilly, David Ryan, Tara Seery, Somasundaram Subramaniam, David Van Echo, Andrea Wang-Gillam, Colin Weekes, Stephen Welch

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Oncology

Imaging and clinical correlates with regorafenib in metastatic colorectal cancer

Khurum Khan, Stefano Cascinu, David Cunningham, Sun-Young Kim, Eiji Oki, Tara Seery, Lin Shen, Salvatore Siena, Christophe Tournigand, Nazim Serdar Turhal, Alain Hendlisz

CANCER TREATMENT REVIEWS (2020)

Add to Collection

Meeting Abstract Oncology

Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.

Tara Elisabeth Seery, Mira Kistler, John H. Lee, Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Immunotherapy combining NK and T cell activation with IL-15 super agonist (N-803), off-the-shelf high-affinity CD16 NK (haNK) or PDL1 targeted haNK and checkpoint inhibitor in relapsed/refractory advanced pancreatic cancer.

Tara Elisabeth Seery, Mira Kistler, Chaitali Singh Nangia, Christina Ann To, Sandeep K. Reddy, Leonard S. Sender, John H. Lee, Patrick Soon-Shiong

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients.

Sandeep K. Reddy, Tara Elisabeth Seery, Christopher Szeto

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

C. Nangia, P. Soon-Shiong, S. Rabizadeh, J. H. Lee, L. Sender, F. Jones, M. Kistler, K. Niazi, T. Seery, A. Rock, O. Jafari

ANNALS OF ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

A phase IB/II randomized study of mFOLFIRINOX (mFFOX) plus pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).

Ramesh K. Ramanathan, Shannon McDonough, Agop Philip Philip, Sunil R. Hingorani, Jill Lacy, Jeremy S. Kortmansky, Jaykumar Ranchodbhai Thumar, E. Gabriela Chiorean, Anthony Frank Shields, Deepti Behl, Paul Tracy Mehan, Rakesh Gaur, Tara Elisabeth Seery, Katherine Guthrie, Howard S. Hochster

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.